🐂 Not all bull runs are created equal. November’s AI picks include 5 stocks up +20% eachUnlock Stocks

Wegovy, Saxenda, Ozempic shortages prompt Morgan Stanley to bump its global obesity market forecast

Published 07/21/2023, 07:50 PM
© Reuters.
LLY
-
NOVOb
-
NVO
-

Morgan Stanley (NYSE:MS) analysts raised their forecast for the global obesity market by over 40% in response to the supply shortages.

Analysts now see the market hitting $77 billion in 2030, up from the prior forecast of $54B.

“The uptake of obesity medicines in the US over the past 12 months has been stronger than we had anticipated, whilst indirectly supporting a profound acceleration in the use of GLP-1 medicines in diabetes,” they said in a note

The analysts note that patient demand for this type of medicine “has outstripped drug supply,” mostly due to fueled by social media activity.

“Reimbursement for obesity medicines has expanded much faster than we had anticipated, covering 40m lives in the US, which exceeds the total number of people estimated to be suffering from diabetes. We estimate that Wegovy sales in the US would have exceeded $7bn in 2023 without the advent of supply chain shortages,” they added.

In this context, the analysts see Novo Nordisk (NYSE:NVO), the manufacturer of Wegovy, Ozempic, and Saxenda treatments, and Mounjaro-producer Eli Lilly (NYSE:LLY), as clear "diabesity" leaders. These two are projected to have an 82% combined market share.

“Our updated obesity market model forecasts suggest ~26% upside potential to the Eli Lilly and Novo Nordisk 2030 group revenue estimates in our company models, with pivotal data for their next generation of obesity medicines reading out in 2025-26, carrying the potential to offset pricing and competitive risks and open up new treatment opportunities.”

 
 

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.